MedTrace Logo

Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma

NCT01411579 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2014-12-10

No results posted yet for this study

Summary

One of the most recent and interesting field of diagnostic imaging is diffusion-weighted MR imaging (DW-MRI). Various studies evaluated the application of DW-MRI to diffuse liver disease and focal liver lesions providing controversial results, probably due to the difficult reproducibility of the apparent diffusion coefficient (ADC) measurements. It is conceivable that a wide inter/intra-individual variability actually exists in the apparent diffusion coefficient (ADC)-values, and that each apparent diffusion coefficient (ADC)-value presents an higher reliability in measuring the temporal changes of water diffusion within the same individual (longitudinal-evaluation), than in characterizing tissues between different patients (transverse-evaluation). For these reasons, some previous studies assessed the application of DW-MRI in predicting the chemotherapy (CHT) outcome in liver metastases. The rationale of these studies was the overt biochemical changes shown by the neoplastic cells after CHT and the sensitivity of DW-MRI in the identification of such changes. The same authors noticed that the metastatic lesions with the lowest ADC-values present also the best outcome after CHT. Moreover, these studies suggest that it could be possible to assess if each single patient will respond (R) or not (NR) to the CHT through liver DW-MRI performed from 3 days to 3 weeks after the beginning of CHT.

Conditions

  • Liver Metastases
  • Hepatocarcinoma

Sponsors & Collaborators

  • Società Italiana Radiologia Medica SIRM

    collaborator UNKNOWN

  • Treviso cà Foncello Hospital

    collaborator UNKNOWN

  • University of Trieste

    collaborator OTHER

  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

    collaborator OTHER

  • Santa Maria delle Grazie Hospital

    collaborator OTHER

  • Azienda Ospedaliera Niguarda Cà Granda

    collaborator OTHER

  • University of Rome Tor Vergata

    collaborator OTHER

  • Stefano Colagrande

    lead OTHER

Principal Investigators

  • Stefano Colagrande, MD · University of Florence

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-02-29
Completion
2013-02-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01411579 on ClinicalTrials.gov